Search | TVST | ARVO Journals

Showing 1 – 20 of 91

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Artificial Intelligence October 2024

Automated Identification of Clinically Relevant Regions in Glaucoma OCT Reports Using Expert Eye Tracking Data and Deep Learning

PDF

Ye Tian; Anurag Sharma; Shubh Mehta; Shubham Kaushal; Jeffrey M. Liebmann; George A. Cioffi; Kaveri A. Thakoor
TAGS: eye-tracking, glaucoma, deep learning, training
Trans. Vis. Sci. Tech.. 2024; 13(10):24. https://doi.org/10.1167/tvst.13.10.24

ARVO Annual Meeting Abstract June 2024

OCT metrics for the macular region are more sensitive for detecting glaucomatous progression than OCT circumpapillary metrics

Iván Marin-Franch; Yujia Wang; Gustavo De Moraes; Ari Leshno; Aakriti Garg Shukla; Jeffrey M Liebmann; George A Cioffi; Donald C Hood; Emmanouil (Manos) Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1451.

ARVO Annual Meeting Abstract June 2024

Perimetric testing patterns focusing on the central visual field region can be more sensitive to glaucomatous progression than more peripheral patterns

Yujia Wang; Iván Marin-Franch; Carlos Gustavo De Moraes; Ari Leshno; Aakriti Garg Shukla; Jeffrey M Liebmann; George A. Cioffi; Donald Hood; Emmanouil Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4800.

ARVO Annual Meeting Abstract June 2024

Use of Topographical Structure–Function Agreement For Glaucoma Screening

Ari Leshno; Donald C Hood; Jeffrey M Liebmann; George A. Cioffi; Aakriti Garg Shukla; Yonatan Shalamaev; Raam Hasharoni; Zvia Burgansky-Eliash; Alon Skaat; Emmanouil (Manos) Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2518.

ARVO Annual Meeting Abstract June 2024

Eyes with particular patterns of retinal ganglion cell damage at baseline are more likely to show glaucomatous progression

Grace Mao; Yujia Wang; Elizabeth Ahn; Ari Leshno; Gustavo De Moraes; Aakriti Garg Shukla; George A Cioffi; Jeffrey M Liebmann; Donald C Hood; Emmanouil Tsamis

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2517.

ARVO Annual Meeting Abstract June 2024

A Randomized, Sham Controlled, Masked Phase II Study for Safety of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma: Adverse Events and Structural Outcomes

Alexandria Dominguez; Gala Beykin; Mariana Nunez; Zac Wennberg Smith; George A. Cioffi; Jeffrey M Liebmann; Marzhan Atakulova; Davinder S. Grover; Jennifer Rinn; Alexus Schley; Jeffrey Louis Goldberg

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):942.

ARVO Annual Meeting Abstract June 2024

Racial and ethnic differences in baseline glaucoma disease severity

Sophie Gu; Ari Leshno; Aakriti Garg Shukla; George A Cioffi; Jeffrey M Liebmann

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2510.

ARVO Annual Meeting Abstract June 2024

A combination of OCT metrics can detect glaucoma progression sooner than a VF benchmark criterion

Emmanouil (Manos) Tsamis; Yujia Wang; Ari Leshno; Carlos Gustavo De Moraes; Aakriti Garg Shukla; George A Cioffi; Jeffrey M Liebmann; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2537.

ARVO Annual Meeting Abstract June 2024

Can modifiable behavioral factors be identified to increase activation in patients with glaucoma?

Alan R Morse; Lisa A Hark; Prakash Gorroochurn; Rebecca Rojas; William H Seiple; Aakriti Garg Shukla; Yujia Wang; Stefania Maruri; Desiree Henriquez; Noga Harizman; Qing Wang; Jeffrey M Liebmann; George A. Cioffi

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4044.

Glaucoma January 2024

Detecting Established Glaucoma Using OCT Alone: Utilizing an OCT Reading Center in a Real-World Clinical Setting

PDF

Ari Leshno; Emmanouil Tsamis; Sitara Hirji; Gabriel A. Gomide; Noga Harizman; Carlos Gustavo De Moraes; Aakriti Garg Shukla; George A. Cioffi; Donald C. Hood; Jeffrey M. Liebmann
TAGS: diagnostic imaging, glaucoma, reading (activity), eye
Trans. Vis. Sci. Tech.. 2024; 13(1):4. https://doi.org/10.1167/tvst.13.1.4

Perspective December 2023

A Model of Progression to Help Identify Macular Damage Due to Glaucoma

PDF

Donald C. Hood; Sol La Bruna; Ari Leshno; Gabriel A. Gomide; Mi Jeung Kim; George A. Cioffi; Jeffrey M. Liebmann; Carlos Gustavo De Moraes; Emmanouil Tsamis
TAGS: glaucoma
Invest. Ophthalmol. Vis. Sci.. 2023; 64(15):8. https://doi.org/10.1167/iovs.64.15.8

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2023

Impact of AI on Retrospective Glaucoma Diagnosis

Joel Salas; Ryan Zukerman; Omar Moussa; Sophie Z. Gu; Ari Leshno; Jeffrey M Liebmann; George Cioffi; Kaveri Thakoor

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):385.

ARVO Annual Meeting Abstract June 2023

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Subanalysis of Falls Risk

Lisa A. Hark; Daniel Diamond; Yujia Wang; Stefania C Maruri; Desiree R. Henriquez; Phyllis Simon; Jason D. Horowitz; Lisa Park; Qing Wang; David S. Friedman; Jeffrey M Liebmann; George Cioffi; Noga Harizman

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2482.

ARVO Annual Meeting Abstract June 2023

Understanding progression of glaucomatous damage in the central macula.

Donald C Hood; Emmanouil Tsamis; Ari Leshno; Gabriel Gomide; Sol La Bruna; George Cioffi; Jeffrey M Liebmann; C. Gustavo De Moraes

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4347.

ARVO Annual Meeting Abstract June 2023

Assessing the progression of glaucoma in the central macular region of ganglion cells using optical coherence tomography (OCT)

Gabriel Gomide; Emmanouil Tsamis; Anna Sun; Grace Mao; Sol La Bruna; Ari Leshno; George Cioffi; Jeffrey M Liebmann; C. Gustavo De Moraes; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4312.

ARVO Annual Meeting Abstract June 2023

A systematic OCT-based approach can improve ophthalmology residents’ performance in glaucoma detection

Sitara Hanif Hirji; Ari Leshno; Emmanouil Tsamis; Alexis Kassotis; Anna J Sun; Gabriel Gomide; Sol La Bruna; Noga Harizman; George Cioffi; Jeffrey M Liebmann; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2015.

ARVO Annual Meeting Abstract June 2023

A Foundational CNN Model for Predicting Eye Fixations on OCT Reports

Anurag Sharma; Ye Tian; Shubham Kaushal; Ryan Zukerman; Royce W.S. Chen; Jeffrey M Liebmann; George Cioffi; Kaveri Thakoor

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):363.

ARVO Annual Meeting Abstract June 2023

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Subanalysis of Glaucoma Suspect Findings

Stefania C Maruri; Qing Wang; Ives Valenzuela; Noga Harizman; Prakash Gorroochurn; Desiree R. Henriquez; Daniel Diamond; Lisa Park; Jason D. Horowitz; James D. Auran; David S. Friedman; C. Gustavo De Moraes; George Cioffi; Jeffrey M Liebmann; Lisa A. Hark

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):126.

ARVO Annual Meeting Abstract June 2023

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Smartphone Ownership to Assess Digital Health Equity

Alexa M. Kaminsky; Prakash Gorroochurn; Stefania C Maruri; Desiree R. Henriquez; Jason D. Horowitz; Lisa Park; Qing Wang; Daniel Diamond; Noga Harizman; James D. Auran; Tarun Sharma; Jeffrey M Liebmann; George Cioffi; Lisa A. Hark

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3071.

ARVO Annual Meeting Abstract June 2023

An evaluation of OCT and visual field measures as endpoints of glaucoma progression

Emmanouil (Manos) Tsamis; C. Gustavo De Moraes; George A Cioffi; Jeffrey M Liebmann; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4310.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Automated Identification of Clinically Relevant Regions in Glaucoma OCT Reports Using Expert Eye Tracking Data and Deep Learning

OCT metrics for the macular region are more sensitive for detecting glaucomatous progression than OCT circumpapillary metrics

Perimetric testing patterns focusing on the central visual field region can be more sensitive to glaucomatous progression than more peripheral patterns

Use of Topographical Structure–Function Agreement For Glaucoma Screening

Eyes with particular patterns of retinal ganglion cell damage at baseline are more likely to show glaucomatous progression

A Randomized, Sham Controlled, Masked Phase II Study for Safety of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma: Adverse Events and Structural Outcomes

Racial and ethnic differences in baseline glaucoma disease severity

A combination of OCT metrics can detect glaucoma progression sooner than a VF benchmark criterion

Can modifiable behavioral factors be identified to increase activation in patients with glaucoma?

Detecting Established Glaucoma Using OCT Alone: Utilizing an OCT Reading Center in a Real-World Clinical Setting

A Model of Progression to Help Identify Macular Damage Due to Glaucoma

Impact of AI on Retrospective Glaucoma Diagnosis

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Subanalysis of Falls Risk

Understanding progression of glaucomatous damage in the central macula.

Assessing the progression of glaucoma in the central macular region of ganglion cells using optical coherence tomography (OCT)

A systematic OCT-based approach can improve ophthalmology residents’ performance in glaucoma detection

A Foundational CNN Model for Predicting Eye Fixations on OCT Reports

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Subanalysis of Glaucoma Suspect Findings

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT) Cluster-Randomized Clinical Trial: Smartphone Ownership to Assess Digital Health Equity

An evaluation of OCT and visual field measures as endpoints of glaucoma progression

To View More...

You must be signed into an individual account to use this feature.